The Global Alliance for TB Drug Development (TB Alliance) and Drugs for Neglected Diseases initiative (DNDi) announced today a unique first-ever royalty-free license agreement between two not-for-profit drug developers that speeds progress toward markedly improved therapy of multiple neglected diseases. The TB Alliance has granted rights to DNDi to develop a class of potential anti-TB compounds that also show significant promise for treating other neglected diseases that largely affect the world's poor. This agreement highlights the efficiency and synergy of product development partnerships (PDPs), and how investment in PDPs is producing a robust and diverse pipeline of tools to treat a wide variety of neglected diseases.
“Developing drugs to fight neglected diseases, like tuberculosis, is about restoring to the world's poor one of the most fundamental human rights — their health”
PDPs build partnerships between the public, private, academic, and philanthropic sectors to drive the development of new medical treatments, vaccines and diagnostics for underserved markets. The TB Alliance is a not-for-profit PDP searching for better and faster cures for tuberculosis. DNDi is a not-for-profit PDP working to research and develop new treatments for other neglected diseases, in particular human African trypanosomiasis (HAT), leishmaniasis, and Chagas' disease.
"Developing drugs to fight neglected diseases, like tuberculosis, is about restoring to the world's poor one of the most fundamental human rights — their health," said Mel Spigelman, M.D., President and CEO, TB Alliance. "We are proud to join with DNDi to speed the development of compounds from our pipeline for new cures for multiple diseases, especially those affecting populations living in abject poverty. This agreement enables us to achieve a common goal and is a testament to the strength and efficiency of the product development partnership model."
Under the agreement, the TB Alliance grants DNDi the rights to develop a series of compounds from the nitroimidazole class for use against many neglected tropical diseases, including visceral leishmaniasis, HAT or sleeping sickness, and Chagas disease. The TB Alliance will also share its scientific expertise and specific knowledge of the drug class, as gained through ongoing work with these compounds. The series of compounds covered by this agreement, designed and synthesized in collaboration with a medicinal chemistry group led by Professor William A. Denny at University of Auckland, New Zealand, is currently under development by the TB Alliance for its potential to yield new TB drug candidates. One of the furthest advanced and most promising TB drug candidates, PA-824, is a nitroimidazole, and is currently in Phase II testing.